The effection and mechanism of Fudosteine used in hypertension patients company with obstructive sleep apnea

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003690

Enrollment

Unknown

Registered

2013-08-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension complicated with obstructive sleep apnea syndrome

Interventions

A group:patients treated with drug A(Fudosteine or placebo

B group:patients treated with drug A(Fudosteine or placebo)

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The age of patients range from 40 to 80 years; 2) Identified essential hypertension patients with sufficient drug treatment and 3) The patients above tested by PSG and AHI>=15(moderate and severe OSA patients).

Exclusion criteria

Exclusion criteria: 1) Patients with severe complications and dysfunction in memory, perception, behavior; 2) Patients with severe respiratory diseases such as COPD, ILD; 3) Severe stroke, AMI emerging within half a yearPatients of NYHA III-IV; 4) Patients with malignancy; 5) Other secondary hypertension such as primary aldosteronism, hypercortisolism, chromaffinoma, Renal hypertension.

Design outcomes

Primary

Measure	Time frame
blood pressure;Flow-mediated diamete;	—

Secondary

Measure	Time frame
biochemical indicator (Glu, Ins, TC, Chol, CRP, homocysteine);biochemical indicator such as Glu, Ins, TC, Chol, CRP, homocysteine;Oxidant stress indicator (NO, SOD, NADPH, MDA, ONOO-);Oxidant stress indicator (NO, SOD, NADPH, MDA, ONOO);	—

Countries

China

Contacts

Public ContactLiu Jiannan

Jiangsu Geriatric Hospital

liujiannan@163.com+86 13912945908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026